DE1617593A1 - Verfahren zur Herstellung von Tabletten oder Pillen - Google Patents
Verfahren zur Herstellung von Tabletten oder PillenInfo
- Publication number
- DE1617593A1 DE1617593A1 DE19661617593 DE1617593A DE1617593A1 DE 1617593 A1 DE1617593 A1 DE 1617593A1 DE 19661617593 DE19661617593 DE 19661617593 DE 1617593 A DE1617593 A DE 1617593A DE 1617593 A1 DE1617593 A1 DE 1617593A1
- Authority
- DE
- Germany
- Prior art keywords
- tablets
- substance
- release
- active substance
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006187 pill Substances 0.000 title claims description 13
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 239000000126 substance Substances 0.000 claims description 44
- 239000013543 active substance Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 8
- 230000000968 intestinal effect Effects 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- 239000000155 melt Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 description 42
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 8
- 239000003814 drug Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000004203 carnauba wax Substances 0.000 description 2
- 235000013869 carnauba wax Nutrition 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- -1 spermacetus Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 206010012186 Delayed delivery Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012170 montan wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- BSFJGCCAXDCMOX-UHFFFAOYSA-N sodium;(4-aminophenyl)sulfonyl-(4-methylpyrimidin-2-yl)azanide Chemical class [Na+].CC1=CC=NC([N-]S(=O)(=O)C=2C=CC(N)=CC=2)=N1 BSFJGCCAXDCMOX-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/003—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic followed by coating of the granules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/006—Coating of the granules without description of the process or the device by which the granules are obtained
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK522265 | 1965-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1617593A1 true DE1617593A1 (de) | 1971-04-29 |
Family
ID=8140572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19661617593 Pending DE1617593A1 (de) | 1965-10-12 | 1966-09-24 | Verfahren zur Herstellung von Tabletten oder Pillen |
Country Status (11)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2810141A1 (de) * | 1977-03-16 | 1978-09-28 | Berri Balzac | Verfahren zur herstellung von presskoerpern, insbesondere tabletten, mit labilen substanzen in mikrodispersion |
| WO1999002134A3 (de) * | 1997-07-10 | 1999-05-14 | Dresden Arzneimittel | Verfahren zur herstellung von wirkstoff-zubereitungen mit kontrollierter freisetzung aus einer matrix |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH574245A5 (enrdf_load_stackoverflow) * | 1971-06-04 | 1976-04-15 | Boehringer Mannheim Gmbh | |
| JPS5031022A (enrdf_load_stackoverflow) * | 1973-05-29 | 1975-03-27 | ||
| US4673527A (en) * | 1985-05-20 | 1987-06-16 | Autotrol Corporation | Tablet granulation |
| JPH03232814A (ja) * | 1990-02-08 | 1991-10-16 | Shin Etsu Chem Co Ltd | 徐放性錠剤の製造方法 |
| ES2096103T3 (es) * | 1992-01-13 | 1997-03-01 | Pfizer | Preparacion de comprimidos de resistencia incrementada. |
| CN110368371A (zh) * | 2014-04-08 | 2019-10-25 | 越洋医药开发(广州)有限公司 | 一种新型控释片 |
-
1966
- 1966-09-24 DE DE19661617593 patent/DE1617593A1/de active Pending
- 1966-10-06 GB GB4463266A patent/GB1137156A/en not_active Expired
- 1966-10-07 FI FI264266A patent/FI48245B/fi active
- 1966-10-11 FR FR1602625D patent/FR1602625A/fr not_active Expired
- 1966-10-11 NO NO16510066A patent/NO126201B/no unknown
- 1966-10-11 SE SE6613760A patent/SE337281C/xx unknown
- 1966-10-12 BE BE688121A patent/BE688121A/xx unknown
- 1966-10-12 BR BR18360666A patent/BR6683606D0/pt unknown
- 1966-10-12 CA CA972,775A patent/CA983393A/en not_active Expired
- 1966-10-12 NL NL6614357A patent/NL6614357A/xx unknown
- 1966-10-13 ES ES332215A patent/ES332215A1/es not_active Expired
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2810141A1 (de) * | 1977-03-16 | 1978-09-28 | Berri Balzac | Verfahren zur herstellung von presskoerpern, insbesondere tabletten, mit labilen substanzen in mikrodispersion |
| WO1999002134A3 (de) * | 1997-07-10 | 1999-05-14 | Dresden Arzneimittel | Verfahren zur herstellung von wirkstoff-zubereitungen mit kontrollierter freisetzung aus einer matrix |
| US6103264A (en) * | 1997-07-10 | 2000-08-15 | Arzneimittelwerk Dresden Gmbh | Process for preparing a controlled release composition |
Also Published As
| Publication number | Publication date |
|---|---|
| NO126201B (enrdf_load_stackoverflow) | 1973-01-08 |
| ES332215A1 (es) | 1968-05-01 |
| FI48245B (enrdf_load_stackoverflow) | 1974-04-30 |
| NL6614357A (enrdf_load_stackoverflow) | 1967-04-13 |
| BR6683606D0 (pt) | 1973-11-13 |
| SE337281C (enrdf_load_stackoverflow) | 1975-10-20 |
| GB1137156A (en) | 1968-12-18 |
| CA983393A (en) | 1976-02-10 |
| BE688121A (enrdf_load_stackoverflow) | 1967-04-12 |
| SE337281B (enrdf_load_stackoverflow) | 1971-08-02 |
| FR1602625A (en) | 1971-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0069259B1 (de) | Bromhexin-Retardform und Verfahren zu ihrer Herstellung | |
| DE69825165T2 (de) | Arzneimittelform mit zwei überzugs-schichten | |
| DE69730991T2 (de) | Alginsaure enthaltende enterischer ueberzug fuer eine orale zubereitung | |
| DE69011588T2 (de) | Pharmazeutische Formulierungen mit anhaltender Freisetzung. | |
| DE69713367T2 (de) | Verfahren zur herstellung einer pharmazeutischen zusammensetzung mit veränderter wirkstoffsfreisetzung, enthaltend eine matrix | |
| EP0068191A2 (de) | Orale Dipyridamolformen | |
| DE3524572A1 (de) | Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung | |
| DE3314003A1 (de) | Teilbare tablette mit verzoegerter wirkstofffreigabe und verfahren zu deren herstellung | |
| DE69521924T2 (de) | Pharmazeutische Darreichungsformen mit verzögerter Wirkstoffabgabe enthaltend Alfuzosinhydrochlorid | |
| EP0250648A2 (de) | Pharmazeutisches Präparat zur verzögerten Freigabe von Ibuprofen | |
| DE3603564A1 (de) | Pharmazeutische praeparate mit analgetrischer wirksamkeit, sowie deren herstellung und verwendung | |
| DE69008107T2 (de) | Zubereitung mit verzögerter Freigabe eines Hydrochlorids eines basischen Arzneistoffs. | |
| DE1935879C3 (de) | Verfahren zur Herstellung eines pharmazeutischen Lithium-Präparates | |
| DE1088192B (de) | Verfahren zur Herstellung von tablettierbaren oder direkt verwendbaren Arzneimittelgranulaten mit einstellbaren Freigabeeigenschaften | |
| DE1617593A1 (de) | Verfahren zur Herstellung von Tabletten oder Pillen | |
| EP0208144A1 (de) | Ambroxol oder bromhexin enthaltendes arzneimittelgranulat | |
| DE69414863T2 (de) | Behälter, der ein hydrophober arzneimittel enthält | |
| DE1617522A1 (de) | Verfahren zur Herstellung einer Arzneimittelzubereitung | |
| DE2062715C3 (de) | Verfahren zur Herstellung von oral applizierbaren Arzneimittelzubereitungen mit protrahierter Wirkstoffabgabe und Arzneimittelzubereitung | |
| DE1492123A1 (de) | Verfahren zur Herstellung von Arzneipraeparaten in Tablettenform | |
| DE69103724T2 (de) | Pharmazeutische zusammensetzungen mit verzögerter freisetzung zur oralen verabreichung sowie deren herstellungsverfahren. | |
| DE4140172A1 (de) | Retardform fuer ein ibuprofen enthaltendes arzneimittel und seine herstellung | |
| DE1617309C3 (de) | Verfahren zur Herstellung von pharmazeutischen Präparaten mit Vitamingehalt | |
| DE19840152A1 (de) | Calciumvalproat enthaltende pharmazeutische Zusammensetzungen mit retardierter Wirkstoff-Freisetzung, Verfahren zu deren Herstellung und deren Verwendung | |
| DE2621906C2 (enrdf_load_stackoverflow) |